- Home
- TBI vs RZLT Comparison
TBI vs RZLT Comparison
Compare TBI & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- RZLT
- Stock Information
- Founded
- TBI 1985
- RZLT 2010
- Country
- TBI United States
- RZLT United States
- Employees
- TBI N/A
- RZLT N/A
- Industry
- TBI Professional Services
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- TBI Consumer Discretionary
- RZLT Health Care
- Exchange
- TBI Nasdaq
- RZLT Nasdaq
- Market Cap
- TBI 248.3M
- RZLT 283.3M
- IPO Year
- TBI 1996
- RZLT N/A
- Fundamental
- Price
- TBI $6.34
- RZLT $4.53
- Analyst Decision
- TBI Buy
- RZLT Strong Buy
- Analyst Count
- TBI 2
- RZLT 8
- Target Price
- TBI $11.50
- RZLT $12.00
- AVG Volume (30 Days)
- TBI 152.5K
- RZLT 419.2K
- Earning Date
- TBI 02-19-2025
- RZLT 02-12-2025
- Dividend Yield
- TBI N/A
- RZLT N/A
- EPS Growth
- TBI N/A
- RZLT N/A
- EPS
- TBI N/A
- RZLT N/A
- Revenue
- TBI $1,567,393,000.00
- RZLT N/A
- Revenue This Year
- TBI N/A
- RZLT N/A
- Revenue Next Year
- TBI N/A
- RZLT N/A
- P/E Ratio
- TBI N/A
- RZLT N/A
- Revenue Growth
- TBI N/A
- RZLT N/A
- 52 Week Low
- TBI $6.06
- RZLT $1.57
- 52 Week High
- TBI $12.66
- RZLT $6.19
- Technical
- Relative Strength Index (RSI)
- TBI 31.22
- RZLT 41.29
- Support Level
- TBI $7.14
- RZLT $4.50
- Resistance Level
- TBI $7.86
- RZLT $5.28
- Average True Range (ATR)
- TBI 0.44
- RZLT 0.36
- MACD
- TBI -0.14
- RZLT -0.06
- Stochastic Oscillator
- TBI 11.60
- RZLT 4.03
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.